The product contains the active ingredients lincomycin hydrochloride and neomycin sulphate in a sterile aqueous vehicle.
Pharmacodynamic properties
Lincomycin is a lincosaminide antibiotic derived from Streptomyces lincolnensis. It possesses specific activity against Gram-positive bacteria, particularly Staphylococcus species and Streptococcus species and has little or no activity against Gram-negative bacteria such as E.coli (except anaerobes). Lincomycin has good activity against mycoplasma. Lincomycin binds to the 50S sub-unit of the bacterial ribosome, thereby inhibiting protein synthesis of the cell. It is generally regarded as a bacteriostatic compound.
Neomycin is an aminoglycoside antibiotic derived from Streptomyces fradiae. It has a broad spectrum of activity against both Gram-positive bacteria, including Staphylococcus species and Streptococcus species, and Gram-negative bacteria, including Escherichia coli. It is more active against Staphylococcus species than against Streptococcus species. Neomycin binds to the 30S sub-unit of the bacterial ribosome resulting in a malconformation of binding ribosomal protein due to errors in reading the amino acid coding of the mRNA. Neomycin thus compromises translation and hence bacterial protein synthesis.
At high concentrations, the aminoglycosides have also been shown to damage the cellular membrane of bacteria and hence are generally regarded as possessing both bacteriostatic and bactericidal properties.
In vitro studies have demonstrated that lincomycin and neomycin in combination have bactericidal activity against Staphylococcus aureus and Escherichia coli and bacteriostatic activity against streptococci. The combination has also demonstrated synergy against Staphylococcus aureus.
Lincomycin, neomycin and the combination have been shown to be active against both penicillinase and non-penicillinase producing staphylococci.
Pharmacokinetic particulars
After recommended infusion of the product, the following mean concentrations of lincomycin and neomycin were measured in individual treated quarters:
| Concentrations (µg/ml) / Time after first infusion |
Antibiotic | 12 hours (1) | 24 hours (2) | 36 hours | 48 hours |
Lincomycin | 52.7 | 53.5 | 56.9 | 4.6 |
Neomycin | 22.2 | 29.7 | 28.0 | 4.9 |
1 - immediately before second infusion
2 - immediately before third (last) infusion
Antibiotic levels in milk above the MIC-values for target pathogens are sustained for the full dosage period and for at least 12 hours thereafter.